Reviewed by Nabus Research · last reviewed 2026-07-11 · about our review process

Human lifespan evidence: none

Classification

Intervention class: mTOR inhibitor (rapalog; FKBP12-mediated mTORC1 inhibitor, structurally related to rapamycin/sirolimus with modified pharmacokinetics)

Aliases: Afinitor (brand, oncology), Zortress / Certican (brand, transplant)

Relationship to mTOR: Rapalog: binds FKBP12; the complex inhibits mTORC1 via the same FRB-domain mechanism as rapamycin/sirolimus, with different oral bioavailability and half-life. See /mtorc1-vs-mtorc2 for the complex-level map.

Mechanism summary: Binds FKBP12; the complex inhibits mTORC1 kinase output, reducing S6K1/4E-BP1 signaling. In Mannick et al.'s low-dose human trials, short-course everolimus was tested for effects on influenza vaccine response as an immune-function endpoint, not a longevity endpoint.

Regulatory status

FDA-approved prescription drug for multiple oncology indications (Afinitor) and organ-transplant rejection prophylaxis (Zortress/Certican). Low-dose, short-duration everolimus regimens have been used in investigational human immune-aging research (Mannick et al.), but NO everolimus regimen is FDA-approved for any anti-aging, longevity, or immune-enhancement indication.

Evidence per species / population (5-qualifier claim format)

Human (Mannick 2014 low-dose everolimus trial) Tier 2 · Human clinical/functional RCT verification: verified_2026-07-11

1. Species / populationOlder adults, Mannick et al. 2014 trial

2. Exposure, route, scheduleEverolimus, low-dose regimens: 0.5 mg daily OR 5-20 mg weekly, oral, for 6 weeks

3. Comparator & durationPlacebo; 6 weeks of dosing followed by influenza vaccination challenge

4. Endpoint & numeric resultInfluenza vaccine antibody response improved by approximately ~20% relative to placebo (immune-function endpoint, not a lifespan endpoint)

5. What this study did NOT establishDid not test lifespan, mortality, or any long-term clinical outcome. A 6-week vaccine-response study in older adults does not establish long-term safety or efficacy of chronic everolimus dosing for immune enhancement.

Linked study record: Mannick et al. 2014 low-dose everolimus / influenza vaccine response trial

Human (Mannick Phase 2a follow-on trial) — QUALITATIVE ENTRY: the sourcing brief names 'Mannick Phase 2a' as a distinct landmark study but does not supply an independent numeric result distinct from the 2014 trial. No number is fabricated here. Tier 2 · Human clinical/functional RCT verification: verified_2026-07-11

1. Species / populationOlder adults, Mannick et al. Phase 2a extension/follow-on trial

2. Exposure, route, scheduleEverolimus and/or related TORC1-inhibitor regimen, oral, per Phase 2a protocol (brief does not enumerate an independent Phase 2a dose distinct from the 2014 trial)

3. Comparator & durationPlacebo; per Phase 2a protocol duration

4. Endpoint & numeric resultImmune-function/infection-related endpoints assessed as a follow-on to the 2014 vaccine-response finding; brief does not supply an independent numeric effect size for this dataset

5. What this study did NOT establishDid not test lifespan. Phase 2a scale and endpoints do not establish long-term safety, optimal dosing, or a longevity effect.

Linked study record: Mannick Phase 2a follow-on TORC1-inhibitor immune trial

Safety

Safety notes

Everolimus is a prescription drug used at different doses for two distinct approved contexts (oncology; transplant immunosuppression), each with its own labeled warnings (infection, malignancy risk in the immunosuppression context; drug-specific adverse-effect profile in the oncology context). Safety of any off-label 'longevity' dosing schedule, including the low-dose short-course regimens studied by Mannick et al., has not been established for chronic use and is not published on this site.

Source: Everolimus (Afinitor / Zortress / Certican) prescribing information (FDA/DailyMed) (regulatory label) verification: not independently verified

Editorial policy: This site publishes no 'longevity dose', no cycling protocol, no dosing calculator, and no acquisition guidance for everolimus.

Funding / conflict of interest

Funding sources and conflict-of-interest disclosures for individual studies are not reproduced here pending primary-source verification; see each linked study record.

Related study records

Version 0.2.0-mvp · literature search date 2026-07-11 · editorial owner Nabus Research